Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Table 5

Clinical trials for VEGF trap in ovarian cancer.

Trial	Phase	Stage of the disease	Results
Single agent
NCT00327171 (ARD6122, AVE0005)—Completed	II	Platinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer	Preliminary results from 162 randomized patients showed a partial response of 11%. [53]
NCT00396591 (ARD6772)—Completed	II	Platinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer with recurrent symptomatic malignant ascites	First results demonstrated the efficacy of two weekly IV aflibercept in prolonging the time to repeat paracentesis in eight out of ten evaluable patients. [54]
NCT00327444 (EFC6125)—Completed	II/III	Platinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer with recurrent symptomatic malignant ascites	Results are awaited
Combination with chemotherapy (docetaxel)
NCT00436501 (MDA-2006-0329)—ongoing	I/II	Recurrent or persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer	Ongoing

IV: Intravenous, VEGF: Vascular endothelial growth factor.
*Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.